Are these 2 battered ASX healthcare shares too cheap to ignore? It's a question that many investors are asking as the sector faces a challenging period. The recent headlines have been dominated by the struggles of CSL Ltd (ASX: CSL) and Cochlear Ltd (ASX: COH), with Telix Pharmaceuticals Ltd (ASX: TLX) not far behind. But is there more to these stories than meets the eye?
The Cochlear Conundrum
Cochlear's story is a cautionary tale of a once-trusted healthcare giant now facing a crisis of confidence. The company's share price took a nosedive after a disappointing trading update, wiping out 46% of its value in just a few days. This was a stark contrast to its previous reputation as a reliable ASX healthcare performer.
The downgrade in FY26 earnings guidance, from $435 million to $290-330 million, was a major blow. Management cited weaker demand, slower referrals, and disruptions as the culprits. Yet, it's worth noting that Cochlear remains at the forefront of implantable hearing technology, with a significant portion of its revenue dedicated to research and development. The company's long-term investment case may still be intact, especially considering the growing global patient pool with hearing loss.
The analyst community is divided. Jarden's price target of $169 suggests a 70% upside, while Macquarie's cut to $115 and Morgans' hold rating at $107.17 paint a more cautious picture. The question remains: is this a temporary setback or a sign of deeper structural issues?
Telix's Volatile Journey
Telix Pharmaceuticals, on the other hand, has been on a wild ride. The ASX healthcare stock has seen extreme share price swings, with a 43% decline over 12 months. However, it's important to note that Telix already generates commercial revenue, a rare trait among biotech companies. Its lead product, Illuccix, is producing growing sales in the US, providing a solid foundation for the business.
Operating in the expanding radiopharmaceuticals sector, Telix is developing innovative cancer treatments. Its diverse pipeline targeting kidney cancer, brain cancer, and other oncology opportunities adds to its allure. The volatility in its share price can be attributed to the nature of the biotech industry, where positive news can spark rallies, and slower news flow can lead to pullbacks.
Analysts, however, remain overwhelmingly bullish. TradingView data shows a consensus of 16 brokers rating Telix as a buy or strong buy, with an average price target of $24.22, implying a 65% upside. The most optimistic analyst target stands at $31, pointing to a potential 110% gain if the company continues to deliver operational growth.
The Bottom Line
In my opinion, these battered ASX healthcare shares present an intriguing opportunity. While the sector faces challenges, both Cochlear and Telix have unique strengths that could drive recovery. Cochlear's leadership in hearing technology and Telix's commercial revenue and innovative pipeline make them stand out in a crowded market. However, investors should approach with caution, as the road to recovery may be fraught with volatility and uncertainty.
What makes this particularly fascinating is the contrast between the two companies. Cochlear's decline raises questions about the resilience of established healthcare giants, while Telix's volatility highlights the risks and rewards of the biotech sector. From my perspective, these stories underscore the importance of thorough research and a long-term investment strategy in the healthcare space.
